Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study
- 2 September 2005
- journal article
- Published by Springer Science and Business Media LLC in The Esophagus
- Vol. 40 (8), 833-835
- https://doi.org/10.1007/s00535-005-1669-x
Abstract
Botulin toxin (BTX) has been proposed as a potential obesity treatment. In a pilot study, the short-term efficacy and safety of BTX was assessed in eight subjects (four men, four women; median age, 46 years; range, 35–57 years) with severe obesity (median body mass index [BMI], 47.1 kg/m2; range 38.2–56.7 kg/m2) and multiple dietary treatment failures. In a single endoscopic session, 500 UI of BTX-A was injected in the gastric antral region. No clinically significant side effects were observed. In all patients, despite their not being on a specific diet, a reduction of body weight was observed at 1 month (median baseline weight, 124.4 kg vs 121.8 kg at 1 month; P < 0.05). Two treatment-unrelated dropouts were observed. At 4 months, three of the six patients had a further weight loss. The treatment effect was apparently independent of changes in hunger or satiety, or of changes in fasting and postprandial plasma ghrelin and serum leptin, thus suggesting a different pharmacological mechanism. BTX-A treatment appears to be safe and well tolerated by obese patients, while its short-term efficacy varied widely.Keywords
This publication has 6 references indexed in Scilit:
- Gastrointestinal Hormones and Regulation of Food IntakeHormone and Metabolic Research, 2004
- REVIEW: The Use of Botulinum Toxin for the Treatment of Gastrointestinal Motility DisordersDigestive Diseases and Sciences, 2004
- Antral Injections of Botulinum A Toxin for the Treatment of ObesityAnnals of Internal Medicine, 2003
- Botulinum toxin injected in the gastric wall reduces body weight and food intake in ratsAlimentary Pharmacology & Therapeutics, 2000
- Therapeutic Uses of Botulinum ToxinNew England Journal of Medicine, 1991
- Assessment [RETIRED]Neurology, 1990